Financial Performance - The company's revenue for Q1 2022 was ¥321,634,613.20, a decrease of 3.34% compared to ¥332,749,095.49 in the same period last year[4] - Net profit attributable to shareholders was ¥1,957,458.10, down 95.14% from ¥40,247,530.57 year-on-year[4] - Basic and diluted earnings per share fell by 96.35% to ¥0.0072 from ¥0.1974 in the same period last year[4] - Total operating revenue for the first quarter was CNY 321,634,613.20, a decrease of 3.36% from CNY 332,749,095.49 in the previous period[23] - Net profit for the first quarter was CNY 1,249,515.90, compared to CNY 42,112,413.87 in the previous period, indicating a significant decline[24] - Total comprehensive income for the period was CNY 1,250,216.49, a significant decrease from CNY 42,111,305.65 in the previous period[25] Cash Flow and Liquidity - The net cash flow from operating activities improved by 44.22%, reaching -¥26,511,328.02 compared to -¥47,527,361.16 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 26,511,328.02, improving from a net outflow of CNY 47,527,361.16 in the previous period[28] - Cash inflow from operating activities totaled CNY 317,501,584.83, compared to CNY 404,532,070.78 in the previous period, indicating a decrease of approximately 21.5%[27] - Cash outflow from operating activities was CNY 344,012,912.85, down from CNY 452,059,431.94 in the previous period[28] - The company’s cash and cash equivalents decreased to CNY 793,596,679.93 from CNY 884,043,596.62 at the beginning of the year, a drop of 10.24%[20] - Cash and cash equivalents at the end of the period were CNY 749,542,990.39, a decrease from CNY 126,020,364.47 at the end of the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,079,145,718.49, a slight decrease of 0.31% from the previous year-end[5] - Total assets amounted to CNY 2,079,145,718.49, slightly down from CNY 2,085,632,908.86 at the beginning of the year[22] - Total liabilities decreased to CNY 570,849,481.01 from CNY 578,586,887.87, a reduction of 1.27%[21] Accounts and Inventory - Accounts receivable increased by 42.29%, primarily due to seasonal fluctuations in revenue and increased customer accounts[9] - Accounts receivable increased to CNY 250,953,563.50 from CNY 176,373,803.84, reflecting a rise of 42.14%[20] - Inventory decreased to CNY 118,420,173.23 from CNY 153,946,515.54, a decline of 23.05%[20] Shareholder Information - The company reported a total of 7,200,000 shares held by Hangzhou Weianuo Investment Partnership, accounting for 2.65% of the total shares[12] - Gracious Star (HK) Limited holds 6,473,507 shares, representing 2.38% of the total shares[12] - Cherish Star (HK) Limited owns 4,302,456 shares, which is 1.58% of the total shares[12] - The company has a significant shareholder, Jin Liwei, holding 161,099,964 shares, which are restricted until June 17, 2024[15] - The total number of restricted shares at the beginning of the period was 207,171,400, with no new restrictions added during the period[15] - The report indicates that there are no changes in the number of restricted shares during the current period[15] - The company has a total of 3,662,800 shares held by Guotai Junan Securities Asset Management, which is 1.35% of the total shares[12] - The total number of shares held by the top 10 unrestricted shareholders is significant, indicating a concentrated ownership structure[12] - The company has not disclosed any related party transactions among the top shareholders[13] Costs and Expenses - Total operating costs increased to CNY 318,364,386.45, up 12.00% from CNY 284,409,824.47 in the previous period[23] - The company reported a significant increase in research and development expenses to CNY 11,363,742.18 from CNY 10,681,434.75, an increase of 6.38%[23] - The company experienced a 96.31% decline in net profit after deducting non-recurring gains and losses, primarily due to rising raw material and transportation costs[8] Tax and Refunds - The company received CNY 16,995,427.58 in tax refunds, an increase from CNY 13,812,645.55 in the previous period[27] Other Matters - There are no other important matters reported in the quarterly financial report[17]

Financial Performance - The company's revenue for Q3 2021 was ¥236,315,695.47, a decrease of 45.54% compared to the same period last year[3] - The net profit attributable to shareholders was ¥2,086,358.75, down 94.32% year-on-year[3] - The company reported a basic earnings per share of ¥0.0077, a decrease of 95.72% year-on-year[3] - Total operating revenue for Q3 2021 was CNY 866,603,187.41, a decrease of 29.7% compared to CNY 1,233,194,920.14 in the same period last year[23] - Net profit for Q3 2021 was CNY 72,681,807.54, a decline of 58.3% compared to CNY 174,008,599.62 in Q3 2020[25] - The total comprehensive income for Q3 2021 was CNY 72,682,749.57, compared to CNY 174,012,199.71 in the previous period[26] - The net profit attributable to the parent company was CNY 69,449,775.33, down from CNY 168,055,416.95 year-on-year[26] - Basic and diluted earnings per share for the current period were CNY 0.2555, compared to CNY 0.8242 in the previous period[26] Cash Flow - The net cash flow from operating activities was negative at -¥11,005,787.31, representing a decline of 104.59% compared to the previous year[3] - Cash flow from operating activities decreased by 104.59% year-on-year, mainly due to a decline in revenue[12] - The company's cash flow from operating activities showed improvement, with a net cash inflow of CNY 81,485,609.99 compared to CNY 198,340,509.44 in the previous year[24] - Cash inflow from operating activities totaled CNY 1,178,410,016.99, a decrease from CNY 1,369,001,550.73 in the previous period[27] - The net cash flow from operating activities was negative CNY 11,005,787.31, compared to a positive CNY 239,777,362.56 in the previous period[29] - Cash inflow from financing activities was CNY 868,509,922.66, compared to CNY 138,900,000.00 in the previous period[30] - The net cash flow from financing activities was CNY 685,396,074.37, a substantial increase from CNY 35,294,913.31 in the previous period[30] Assets and Liabilities - Total assets increased by 35.04% to ¥2,017,416,377.49 compared to the end of the previous year[4] - The company's total assets increased to CNY 2,017,416,377.49, up from CNY 1,493,966,929.22 year-over-year, representing a growth of 35.0%[21] - Total liabilities decreased to CNY 476,638,525.32 from CNY 812,417,102.08, a reduction of 41.3%[21] - The equity attributable to shareholders rose by 135.55% to ¥1,444,920,510.73 compared to the end of the previous year[4] - The equity attributable to the parent company increased to CNY 1,444,920,510.73, compared to CNY 613,425,459.94 in the previous year, reflecting a growth of 135.5%[21] Expenses - Sales expenses increased by 40.37% compared to the same period last year, primarily due to higher marketing costs[11] - Management expenses rose by 34.37% year-on-year, mainly due to increased expenses related to the company's listing[11] - Research and development expenses for Q3 2021 were CNY 35,968,748.44, down 23.7% from CNY 47,086,194.32 in the same quarter last year[24] - Financial expenses decreased by 144.9% year-on-year, attributed to increased foreign exchange gains and interest income[11] Investments - Investment income surged by 911.53% compared to the previous year, driven by increased financial management of idle funds[11] - Cash flow from investing activities increased by 137.96% year-on-year, due to higher cash payments for investments[12] - Cash outflow from investing activities was CNY 483,027,061.64, significantly higher than CNY 193,847,859.19 in the previous period[30] - The net cash flow from investing activities was negative CNY 361,111,800.16, compared to negative CNY 151,750,125.56 in the previous period[30] Shareholder Information - The top shareholder, Jin Liwei, holds 59.26% of the shares, indicating significant control over the company[14] - The company established a new subsidiary, increasing minority interests by 40.71%[10] Future Outlook - The company plans to focus on market expansion and new product development to drive future growth[24] Cash and Equivalents - Cash and cash equivalents increased by 80.70% compared to the beginning of the year, primarily due to funds raised from the initial public offering[9] - The company's cash and cash equivalents increased to approximately ¥613 million as of September 30, 2021, compared to ¥339 million at the end of 2020[18] - The ending cash and cash equivalents balance was CNY 528,934,637.23, up from CNY 230,561,802.44 in the previous period[30]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15% compared to RMB 435 million in the same period of 2020[16]. - The net profit attributable to shareholders for the first half of 2021 was RMB 80 million, up 20% from RMB 66.67 million in the first half of 2020[16]. - Future guidance estimates a revenue growth of 20% for the full year 2021, projecting total revenue to reach RMB 1.2 billion[16]. - The company's operating revenue for the reporting period was ¥630,287,491.94, a decrease of 21.14% compared to the same period last year[22]. - The net profit attributable to shareholders was ¥67,362,474.55, down 48.71% year-over-year[22]. - The net cash flow from operating activities was ¥18,099,870.28, reflecting a significant decline of 89.81% compared to the previous year[22]. - The company reported a decrease in accounts payable to RMB 241,477,124.50 from RMB 256,887,154.13, which is a reduction of approximately 6.0%[145]. - The net profit for the first half of 2021 was ¥54,387,426.50, down 49.5% from ¥107,683,498.23 in the same period last year[158]. - The company's operating cash flow for the first half of 2021 was ¥18,099,870.28, a significant decline of 89.8% compared to ¥177,543,317.82 in the first half of 2020[161]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2022[16]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of RMB 100 million allocated for this purpose[16]. - The company aims to increase its market share through strategic partnerships and potential acquisitions in the healthcare sector[171]. - The company plans to invest heavily in product research and development, channel expansion, and brand building to mitigate risks associated with market competition[78]. - The company has established strategic partnerships with major pharmaceutical distribution companies to enhance brand coverage and influence[51]. Research and Development - The company has invested RMB 50 million in R&D for new product development, focusing on eco-friendly materials and innovative designs[16]. - Research and development investment was ¥23,633,763.81, down 16.41% from ¥28,274,056.90, reflecting a reduction in R&D spending[55]. - The company has allocated resources for research and development to innovate new products and technologies[171]. - The company holds 247 patents, including 41 invention patents, showcasing its strong R&D capabilities[47]. Financial Position - Total assets increased by 45.61% to ¥2,175,431,195.08 compared to the end of the previous year[22]. - The net assets attributable to shareholders rose by 135.13% to ¥1,442,344,319.90 compared to the end of the previous year[22]. - The company's total assets included cash of ¥1,060,638,789.04, representing 48.76% of total assets, significantly increased due to IPO proceeds[60]. - The company's equity attributable to shareholders increased to RMB 1,442,344,319.90 from RMB 613,425,459.94, marking a substantial rise of around 134.0%[146]. - The total assets at the end of the reporting period amounted to CNY 1,401,420,000, indicating a robust financial position[177]. Operational Efficiency - The gross margin for the first half of 2021 was reported at 35%, slightly down from 37% in the same period last year due to increased raw material costs[16]. - The operating cost decreased by 11.25% to ¥478,708,424.20 from ¥539,417,494.45, also attributed to the decline in sales of epidemic prevention materials[54]. - The company has implemented new strategies to enhance operational efficiency and reduce costs[171]. Shareholder Information - The company will not distribute cash dividends for the current fiscal year, opting to reinvest profits into business expansion[6]. - The company has not distributed cash dividends or bonus shares for the half-year period and has no plans for capital reserve conversion into share capital[88]. - The total number of shares outstanding is 271,860,000, with 64,806,264 shares being unrestricted[122]. - The largest shareholder, Jin Liwei, holds 161,099,964 shares, representing 59.26% of the total shares[127]. Legal and Compliance - The half-year financial report has not been audited, and there are no significant litigation or arbitration matters reported[99][101]. - The company reported a litigation amount of 13,178.4 thousand yuan related to a contract dispute, which will not impact daily operations[102]. - The company has not reported any penalties or rectifications during the reporting period[103]. - There are no significant related party transactions reported during the period[106]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties for environmental issues during the reporting period[92]. - The company actively participates in social responsibility projects, particularly for the disabled, and has contributed to various charitable activities[93].